Discover
PVLA
Palvella Therapeutics, Inc.
143.94
3 x 100.00
1 x 200.81
bid
ask
+
19.79
15.94%
1 @ 04:00 PM
144.50 +0.56 (0.39%)
| Ytd | 37.52% | |
| 1y | 364.32% |
120.61
day range
145.98
31.01
52 week range
161.38
| Open | 123.84 | Prev Close | 124.15 | Low | 120.61 | High | 145.98 | Mkt Cap | 1.70B |
| Vol | 364.77K | Avg Vol | 268.68K | EPS | -4.17 | P/E | -34.52 | Forward P/E | -22.15 |
| Beta | -0.20 | Short Ratio | 8.17 | Inst. Own | 96.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 125.57 | 200-d Avg | 106.59 | 1yr Est | 229.60 |
| Income Statement | |||
| Operating Expenses | 14.86M | ||
| Research and Development Expense | 9.33M | ||
| Selling, General and Administrative Expense | 5.52M | ||
| Operating Income | -14.85M | ||
| Interest Expense | 2.04M | ||
| Net Income | -15.77M | ||
| Net Income Common Stock | -15.77M | ||
| Net Income Common Stock (USD) | -15.77M | ||
| Consolidated Income | -15.77M | ||
| Earnings per Basic Share | -1.20 | ||
| Earnings per Basic Share (USD) | -1.20 | ||
| Earnings per Diluted Share | -1.20 | ||
| Earning Before Interest & Taxes (EBIT) | -13.73M | ||
| Earning Before Interest & Taxes (USD) | -13.73M | ||
| Weighted Average Shares | 13.09M | ||
| Weighted Average Shares Diluted | 13.09M | ||
| Balance Sheet | |||
| Cash and Equivalents | 206.39M | ||
| Cash and Equivalents (USD) | 206.39M | ||
| Investments | 55.46M | ||
| Investments Current | 55.46M | ||
| Current Assets | 263.23M | ||
| Property, Plant & Equipment Net | 528.00K | ||
| Total Assets | 263.76M | ||
| Debt Current | 209.00K | ||
| Total Debt | 584.00K | ||
| Current Liabilities | 9.12M | ||
| Debt Non-Current | 375.00K | ||
| Total Liabilities | 31.45M | ||
| Accumulated Retained Earnings (Deficit) | -151.22M | ||
| Accumulated Other Comprehensive Income | 95.00K | ||
| Shareholders Equity | 232.31M | ||
| Shareholders Equity (USD) | 232.31M | ||
| Assets Non-Current | 528.00K | ||
| Total Debt (USD) | 584.00K | ||
| Liabilities Non-Current | 22.33M | ||
| Trade and Non-Trade Payables | 5.44M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 44.00K | ||
| Net Cash Flow from Financing | 214.73M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 148.41M | ||
| Issuance (Purchase) of Equity Shares | 216.71M | ||
| Net Cash Flow from Investing | -55.44M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -55.44M | ||
| Net Cash Flow from Operations | -10.86M | ||
| Effect of Exchange Rate Changes on Cash | -15.00K | ||
| Share Based Compensation | 3.38M | ||